When Positive D-Dimers are Negative

This is the latest article from Jeff Kline, published in Thrombosis and Haemostasis (don’t you all subscribe to that, too?), concerning pulmonary embolism and d-Dimer.

Wouldn’t it be great if the d-Dimer wasn’t a dichotomous cut-off?  Where, if a patient were of sufficiently low pre-test probability, a d-Dimer value that was nearly negative still contributed adequately to a negative likelihood ratio to reduce the probability of a significant pulmonary embolism?  Well, that’s the theory behind this article – which looks at d-Dimer measurements combined with age, Wells’ score, and Revised Geneva scores.

There are a lot of complex tables in this article breaking down the various potential cut-off values for d-Dimer along with different pre-test probabilities, and the concept presented is that potentially higher cut-off values of d-Dimer can be used without missing PEs larger than sub-segmental.  This is presented in context that a higher cut-off might allow reductions in imaging, which seems fair.

However, the most interesting thing in this article to me is Figure 3 – which is d-Dimer concentration compared with fractional obstruction of pulmonary vascular tree.  It is, unfortunately, pretty clear there’s not a great linear relationship between dimer and pulmonary obstruction.  Most low d-Dimers had < 5% obstruction of the vascular tree, but at least one patient with a “negative” d-Dimer had 20% obstruction.  Beyond that, patients were just as likely to have 90% obstruction with modestly elevated d-Dimers than with massively elevated d-Dimers.

“D-dimer threshold increase with pretest probability unlikely for pulmonary embolism to decrease unnecessary computerized tomographic pulmonary angiography”
www.ncbi.nlm.nih.gov/pubmed/22284935

3 thoughts on “When Positive D-Dimers are Negative”

  1. At least the ACEP Clinical Guidelines endorse PERC – which (hopefully) assists in legal defense against missed PEs by acknowledging a zero-miss practice is unrealistic (and potentially impossible).

    Also – we need better outcomes-oriented data on the sorts of PEs that PERC misses if left untreated. Who knows how natural fibrinolytic hemostasis would have managed his clot (and resultant clot burden)? We simply don't know how many undiagnosed PEs are out there; the epidemiologic data clearly shows we're now discovering a _lot_ now that weren't found before, without any change in outcomes….

  2. At least the ACEP Clinical Guidelines endorse PERC – which (hopefully) assists in legal defense against missed PEs by acknowledging a zero-miss practice is unrealistic (and potentially impossible).

    Also – we need better outcomes-oriented data on the sorts of PEs that PERC misses if left untreated. Who knows how natural fibrinolytic hemostasis would have managed his clot (and resultant clot burden)? We simply don't know how many undiagnosed PEs are out there; the epidemiologic data clearly shows we're now discovering a _lot_ now that weren't found before, without any change in outcomes….

Comments are closed.